Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Status Completed

Clinical Trial Summary

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with recurrent or progression meningiomas.

Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine the efficacy of bevacizumab in patients with recurrent or progressive benign and atypical/malignant meningiomas, despite prior therapy, as measured by six-month progression-free survival. SECONDARY OBJECTIVES: I. To describe the response rate and overall-survival in this patient population. II. To evaluate the safety profile of bevacizumab in patients with recurrent meningiomas. III. To perform an exploratory study in patients with hemangioblastoma and hemangiopericytoma. IV. To assess tissue for VEGF and VEGFR to correlate with response. An exploratory analysis of HER-2 will be performed. OUTLINE: Patients receive bevacizumab IV over 30-90 minutes every 2 weeks for 6 months. Patients may then receive bevacizumab IV every 3 weeks for up to 12 months. Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed every 3 months for 2 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01125046
Study type	Interventional
Source	Northwestern University
Contact
Status	Completed
Phase	Phase 2
Start date	June 17, 2010
Completion date	December 31, 2018

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03190915` - Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia	Phase 2
Completed	`NCT03326388` - Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours	Phase 1/Phase 2
Completed	`NCT00026780` - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Active, not recruiting	`NCT01362803` - AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT01218139` - Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients	N/A
Recruiting	`NCT05149469` - Molecular Aspects of Preimplantation Genetic Diagnosis for NF1
Not yet recruiting	`NCT02505412` - Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients	N/A
Terminated	`NCT02256124` - Effect of Lamotrigine on Cognition in NF1	Phase 2/Phase 3
Completed	`NCT01707836` - Neurofibromatosis Type 1 Brain Tumor Genetic Risk	N/A
Active, not recruiting	`NCT01218152` - Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs	N/A
Recruiting	`NCT03975829` - Pediatric Long-Term Follow-up and Rollover Study	Phase 4
Recruiting	`NCT05186870` - Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest
Active, not recruiting	`NCT03231306` - Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas	Phase 2
Withdrawn	`NCT03332030` - Stem Cells in NF1 Patients With Tumors of the Central Nervous System
Recruiting	`NCT02964884` - Interventions for Reading Disabilities in NF1	Phase 2
Recruiting	`NCT05388370` - PASS of Paediatric Patients Initiating Selumetinib
Recruiting	`NCT02777775` - Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Completed	`NCT02944032` - Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1	N/A
Completed	`NCT01851135` - Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1	N/A
Completed	`NCT01410006` - Neurofibromatosis Type 1 Patient Registry	N/A